LYONS GARY A 4

What Happened

• Gary A. Lyons, a director of Travere Therapeutics (TVTX), exercised stock options and sold the underlying shares on April 14, 2026. The filing shows an exercise of 8,000 shares at $16.33 per share (cash cost $130,640) and an immediate open-market sale of those 8,000 shares at $41.07 per share for $328,560 in proceeds. The same filing also reports an additional acquisition of 8,000 shares at a $0.00 price reported as a derivative conversion.
• The sale was executed under a pre-established Rule 10b5-1 trading plan; the stock option involved was fully vested and exercisable.

Key Details

• Transaction date: April 14, 2026.
• Exercise: 8,000 shares at $16.33 each (cost $130,640).
• Sale: 8,000 shares at $41.07 each (proceeds $328,560).
• Additional reported acquisition: 8,000 shares at $0.00 (reported as a derivative conversion).
• Footnotes: Sale made pursuant to a written 10b5-1(c) plan adopted Nov 11, 2025; option is fully vested and exercisable.
• Shares owned after the transactions are not shown in the provided excerpt — see the full Form 4 for current beneficial ownership.
• Filing date: April 16, 2026 (filed within the typical 2-business-day window following the April 14 transaction).

Context

• This was an option exercise followed by an immediate sale of the exercised shares (commonly a cashless or same-day disposition). Such transactions are often routine when covered by a 10b5-1 plan and do not necessarily signal company-specific views by the insider.
• Purchases generally carry more weight as a signal of confidence; this filing documents liquidity from option exercise and a pre-planned sale. For full details, review the complete Form 4 (Accession 0001123343-26-000002).